Resmetirom Shows Promise in Preventing Fatty Liver Cancer | HKUMed Research

A drug already approved by the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD) is showing promise in a fresh area: potentially preventing and suppressing liver cancer. Researchers at the University of Hong Kong (HKUMed) have published findings in the journal Hepatology detailing how Resmetirom, the drug in question, appears to offer benefits beyond simply reducing liver fat, and fibrosis.

Fatty Liver Disease and the Rising Risk of Liver Cancer

Liver cancer, specifically hepatocellular carcinoma (HCC), is a significant global health concern, ranking as the sixth most common cancer worldwide and the third leading cause of cancer-related death. The increasing prevalence of obesity, diabetes, and metabolic syndrome is driving a parallel rise in fatty liver disease – and liver cancer linked to metabolic disorders. Approximately 3% of individuals with fatty liver disease develop liver cancer annually, a burden particularly acute in Asia, where an estimated quarter of the population is affected. HKUMed’s press release highlights this growing connection.

Currently, treatments like immune checkpoint inhibitors exist for advanced liver cancer, but their effectiveness is limited in patients whose cancer originates from fatty liver disease. The reasons for this reduced efficacy remain unclear, prompting researchers to investigate the underlying mechanisms and explore new therapeutic strategies for those at high risk.

How Resmetirom Works: A Focus on Midkine

The HKUMed team’s research centered on a mouse model designed to closely mimic human fatty liver and MAFLD. Their investigation revealed a key role for a protein called Midkine. The study suggests that Midkine weakens the immune system, creating a more favorable environment for cancer development. Resmetirom appears to counteract this effect, offering a potential pathway for both preventing and suppressing tumor growth. While the exact mechanisms are still being investigated, the findings suggest Resmetirom isn’t just treating the symptoms of fatty liver disease, but potentially addressing a fundamental driver of cancer progression.

Beyond Liver Fat: Understanding MAFLD and its Complications

Metabolic dysfunction-associated fatty liver disease (MAFLD) – formerly known as non-alcoholic fatty liver disease (NAFLD) – is a condition where excess fat accumulates in the liver in individuals who do not consume excessive amounts of alcohol. It’s closely linked to metabolic syndrome, a cluster of conditions including high blood pressure, high blood sugar, abnormal cholesterol levels, and excess abdominal fat. Mirage News reports on the study’s findings, emphasizing the broader implications of MAFLD beyond liver health.

The progression of MAFLD can lead to inflammation, liver damage (fibrosis), and cirrhosis. Cirrhosis significantly increases the risk of developing liver cancer. The discovery that Resmetirom may interrupt this progression, and even reverse some of the damage, is a significant development.

Study Limitations and the Path Forward

It’s crucial to emphasize that this research was conducted in a mouse model. While these models are designed to replicate human disease, they are not perfect substitutes. Results observed in mice do not automatically translate to humans. Further research, including clinical trials, is necessary to determine whether Resmetirom has the same preventative and suppressive effects on liver cancer in human patients.

The study also focused specifically on liver cancer arising from fatty liver disease. It’s currently unclear whether Resmetirom would be effective against other types of liver cancer or cancers originating in other parts of the body. The research team acknowledges the demand for further investigation into the drug’s broader anti-cancer potential.

What Which means for Patients

This research does *not* mean that individuals with fatty liver disease should immediately start taking Resmetirom to prevent cancer. The drug is currently approved by the FDA only for treating MAFLD, and its use should be guided by a qualified healthcare professional. Patients with concerns about their risk of liver cancer should discuss their individual circumstances with their doctor, focusing on managing underlying conditions like obesity, diabetes, and metabolic syndrome through lifestyle modifications and appropriate medical care.

Next Steps: Clinical Trials and Further Research

The HKUMed team’s findings provide a strong rationale for conducting clinical trials to evaluate the efficacy of Resmetirom in preventing and treating liver cancer in humans. These trials would need to carefully assess the drug’s safety and effectiveness, as well as identify which patients are most likely to benefit. PublicNow also covered the study, noting the potential for new therapeutic approaches.

Beyond clinical trials, further research is needed to fully understand the mechanisms by which Resmetirom exerts its anti-cancer effects. Specifically, researchers will need to investigate how the drug interacts with Midkine and the immune system, and whether other factors contribute to its observed benefits. This deeper understanding could lead to the development of even more effective strategies for preventing and treating liver cancer.